Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Common Equity (2016 - 2025)

Spyre Therapeutics' Common Equity history spans 11 years, with the latest figure at $715.2 million for Q4 2025.

  • For Q4 2025, Common Equity rose 38.13% year-over-year to $715.2 million; the TTM value through Dec 2025 reached $715.2 million, up 38.13%, while the annual FY2025 figure was $715.2 million, 38.13% up from the prior year.
  • Common Equity reached $715.2 million in Q4 2025 per SYRE's latest filing, up from $455.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $715.2 million in Q4 2025 to a low of -$245.4 million in Q3 2023.
  • Average Common Equity over 5 years is $196.9 million, with a median of $121.4 million recorded in 2021.
  • Peak YoY movement for Common Equity: tumbled 463.26% in 2023, then soared 352.48% in 2024.
  • A 5-year view of Common Equity shows it stood at $83.9 million in 2021, then tumbled by 40.07% to $50.3 million in 2022, then surged by 265.8% to $184.0 million in 2023, then surged by 181.39% to $517.8 million in 2024, then soared by 38.13% to $715.2 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Common Equity are $715.2 million (Q4 2025), $455.1 million (Q3 2025), and $455.8 million (Q2 2025).